Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
暂无分享,去创建一个
H K Genant | Jacques P. Brown | H. Genant | N. Watts | T. Hangartner | P. Miller | E. Eriksen | S. T. Harris | C. Chesnut | J. Brown | C H Chesnut | C. McKeever | S T Harris | M. Keller | M. Hoseyni | D. Axelrod | P D Miller | E F Eriksen | T Hangartner | N B Watts | C D McKeever | M Keller | J Brown | M S Hoseyni | D W Axelrod | Michael I Keller | Jacques P. Brown
[1] E. Barrett-Connor. Prevalence, Initiation, and Continuation of Hormone Replacement Therapy , 1995 .
[2] S. Cummings,et al. Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.
[3] G E Dallal,et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.
[4] A. Lane,et al. Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.
[5] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[6] S. Majumdar,et al. Noninvasive assessment of bone mineral and structure: State of the art , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] B. Ettinger,et al. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. , 1998, The American journal of managed care.
[8] G. Maconi,et al. Multiple ulcerative esophagitis caused by alendronate. , 1995, The American journal of gastroenterology.
[9] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[10] J. Zanchetta,et al. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases , 1996 .
[11] L. Bouter,et al. Vitamin D Supplementation and Fracture Incidence in Elderly Persons , 1996, Annals of Internal Medicine.
[12] M. Nevitt,et al. Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] H. Genant,et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1993, The American journal of medicine.
[14] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[15] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[16] C. Christiansen,et al. EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .
[17] Ebra,et al. ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE , 2000 .
[18] R. Recker,et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .
[19] H. Genant. Universal standardization for dual X‐ray absorptiometry: Patient and phantom cross‐calibration results , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] Jacques P. Brown,et al. A comparative trial of risedronate vs. etidronate in the treatment of patients with Paget’s disease of bone , 1999 .
[21] P. Steiger. Standardization of postero-anterior (PA) spine BMD measurements by DXA. Committee for Standards in DXA. , 1995, Bone.
[22] V. Ravnikar. Compliance with hormone therapy. , 1987, American journal of obstetrics and gynecology.
[23] M. Dougados,et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. , 1994, Bone.
[24] J. Digennaro,et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. , 1998, The Journal of clinical endocrinology and metabolism.
[25] D. Hosking,et al. Paget's disease of bone: reduction of disease activity with oral risedronate. , 1998, Bone.
[26] M. Dougados,et al. Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma. , 1992, Bone.